基因组编辑工程T细胞用于癌症免疫治疗
Chiara Bonini1, Aude G Chapuis2,3, Michael Hudecek4
1Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy.
Human gene therapy
|September 11, 2023
概括
基因组编辑,特别是CRISPR技术,增强了癌症的采用细胞疗法 (ACT). 这种方法旨在提高工程T细胞的疗效,安全性和适用于更多患者.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 采用细胞疗法 (ACT) 在治疗癌症方面表现有前途,几种工程T细胞产品已被批准用于B细胞恶性瘤.
- 目前的工程T细胞疗法面临着局限性,尽管临床成功.
研究的目的:
- 审查基因组编辑的新兴应用,特别是以RNA为指导的集群定期间隔的短Palindromic重复 (CRISPR) 技术,以推进抗癌采用细胞疗法 (ACT).
- 探索基因组编辑如何解决ACT当前的挑战,包括治疗耐药性,免疫反应和瘤微环境中的T细胞功能.
主要方法:
- 审查与ACT相关的基因转移技术和免疫学见解的最新进展.
- 分析基因组编辑策略的应用,包括CRISPR,以增强工程T细胞用于癌症治疗.
主要成果:
- 基因组编辑可以克服癌症的免疫逃避和对治疗的抗性.
- 它可以减轻来自全原性T细胞产品的不良免疫反应.
- 它增强了工程T细胞的适应性,扩张性,持久性和功效,同时保持安全.
- 它提高治疗细胞抵抗免疫抑制瘤微环境的能力.
结论:
- 基因组编辑技术为采用细胞疗法的当前局限性提供了创新的解决方案.
- 这些进展预计将ACT的安全有效应用扩展到更广泛的各种癌症患者群体.
相关概念视频
Tumor Immunotherapy
554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


